Skip to main content
SpringerLink
Log in
Book cover

Progress in Anti-Cancer Chemotherapy pp 145–152Cite as

Systemic Therapy of Bladder Cancer

  • Chapter

  • 61 Accesses

Part of the book series: Progress in Anti-Cancer Chemotherapy ((ANTI-CANCER,volume 4))

Abstract

Transitional cell carcinoma of the bladder and urinary tract (urothelial cancer) is one of the most common cancers diagnosed in North America. About 75 % of urothelial cancer is superficial, non-invasive Ta and Tl disease. In the majority of cases superficial disease can be dealt with by local rather than systemic therapy using means such as trans-urethral resection and intra-vesical chemotherapy and/or immunotherapy. Metastatic urothelial cancer on the other hand, is a rapidly fatal disease with a median survival of approximately 1 year. It is in this setting that systemic chemotherapy for urothelial cancer has been most rigorously tested. This review will discuss what we know about chemotherapy in metastatic disease as well as to give a brief overview of the role of chemotherapy in locally advanced [muscle invasive] bladder cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Whitmore WF, Yagoda A (1989) Chemotherapy in the management of bladder tumours. Drugs 38:301–312

    Article  PubMed  Google Scholar 

  2. Loehrer PJ, Einhorn LH, Elson PJ et al. (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 10:1066–1073

    PubMed  Google Scholar 

  3. Wagstaff AJ, Ward A, Benfield P et al. (1989) Carboplatin. Drugs 37:162–190

    Article  PubMed  CAS  Google Scholar 

  4. Moore MJ, Tannock IF (1993) Chemotherapy of bladder cancer. In: Advances in Urology. Catalona Wm (ed), Mosby, 6:127–156

    Google Scholar 

  5. Roth BJ, Dreicer R, Einhorn LH et al. (1994) Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Co-operative Oncology Group. J Clin Oncol 12: 2264–2270

    PubMed  CAS  Google Scholar 

  6. Papamichael D, Gallagher CJ, Oliver RT et al. (1997) Phase II study of paclitaxel in pre-treated patients with cancer of the bladder and ureter. Br J Cancer 75:606–607

    Article  PubMed  CAS  Google Scholar 

  7. McCaffrey JA, Hilton S, Mazumdar M et al. (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 15:1853–1857

    PubMed  CAS  Google Scholar 

  8. Hertel LW, Boder GB, Kroin JS et al. (1990) Evaluation of the antitumor activity of gemcitabine. Cancer Res 50:4417–4422

    PubMed  CAS  Google Scholar 

  9. Pollera CF, Ceribelli A, Crecco M et al. (1994) Weekly gemcitabine in advanced bladder cancer. Ann Oncol 5:182–185

    PubMed  CAS  Google Scholar 

  10. DeLena M, Gridelli C, Lorusso V et al. (1996) Gemcitabine activity in resistant stage IV bladder cancer. Proc Am Soc Clin Oncol 15:246

    Google Scholar 

  11. Moore MJ, Tannock IF, Ernst DS et al. (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441–3445.

    PubMed  CAS  Google Scholar 

  12. Stadler WM, Kuzel T, Roth B et al. (1997) Phase II trial of gemcitabine in previously untreated patients with urothelial cancer. J Clin Oncol 14:3394–3398

    Google Scholar 

  13. Sternberg CN, Yagoda A, Scher HI et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458

    CAS  Google Scholar 

  14. Tannock IF, Gospodarowicz M, Connolly J et al. (1989) M-VAC chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital Experience. J Urol 142:289–292

    PubMed  CAS  Google Scholar 

  15. Fossa SD, Scher HI, Sternberg C et al. (1996) Survival of patients with advanced urothelial cancer treated with cisplatin based therapy. Br J Urol

    Google Scholar 

  16. Saxman SB, Loehrer PJ, Propert K et al. (1997) Long term follow up of phase III intergroup study of M-VAC vs. cisplatin in metastatic urothelial carcinoma. J Clin Oncol 15:2564–2569

    PubMed  CAS  Google Scholar 

  17. Miller RS, Freiha FS, Reese JH et al. (1993) CMV plus surgical restaging for patients with advanced urothelial cancer. J Urol 150:65–69

    PubMed  CAS  Google Scholar 

  18. Redman, BG, Smith DC, Flaherty L et al. (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844–1848

    PubMed  CAS  Google Scholar 

  19. Bajorin Dr, McCaffrey JA, Hilton S et al. (1998) Treatment of patients with transitional cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: A phase II trial. J Clin Oncol 16:2722–2727

    PubMed  CAS  Google Scholar 

  20. Sengelov L, Kamby C, Lund B et al. (1998) Docetaxel and cisplatin in metastatic urothelial cancer: A phase II trial. J Clin Oncol 16:3392–3397

    PubMed  CAS  Google Scholar 

  21. MooreMJ, Winquist E, Tannock IF et al. (1999) Gemcitabine plus cisplatin: an active regiment in advanced urothelial cancer. J Clin Oncol (in press Sept 1999)

    Google Scholar 

  22. von der Masse H, Andersen L, Crino L et al. (1997) A phase II study of gemcitabine plus cisplatin in patients with transitional cell carcinoma of the urothelium. Proc ASCO 16:1155

    Google Scholar 

  23. Kaufman D, Stadler WM, Carducci et al. Gemcitabine plus cisplatin in metastatic urothelial cancer (1998) Final results of a phase II study. Proc ASC07:1235

    Google Scholar 

  24. Moore MJ, Tannock If, Iscoe N (1993) A phase II trial of M-VAC plus GM-CSF in metastatic urothelial cancer. J Urol 150:1131–1136

    PubMed  CAS  Google Scholar 

  25. Sternberg C. (1996) Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 23:621–632

    PubMed  CAS  Google Scholar 

  26. Dimopoulos MA, Moulopoulos LA (1998) Role of adjuvant chemotherapy in invasive carcinoma of the bladder. J Clin Oncol 16:1601–1612

    PubMed  CAS  Google Scholar 

  27. Michael M, Tannock IF, Moore MJ et al. (1998) PMH experience with adjuvant chemotherapy for invasive urothelial cancer. Br J Urol 82:366–372

    Article  PubMed  CAS  Google Scholar 

  28. Stockle M, Meyenburg W, Wellek S et al. (1992) Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. J Urol 152:81–84

    Google Scholar 

  29. Esrig D, Elmajian D, Groshen S et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259–1264

    Article  PubMed  CAS  Google Scholar 

  30. Siu LL, Banerjee D, Moore MJ et al. (1998) The prognostic role of p53, metallothionein, P-glycoprotein and MIB-1 in muscle invasive urothelial carcinoma. Clinical Cancer Research 4: 311–315

    Google Scholar 

  31. Martinez-Pineiro JA, Martin MG, Arocena F et al. (1005) Neoadjuvant cisplatin chemotherapy before radical cystectomy ñ a phase II study. J Urol 153:964–973

    Article  Google Scholar 

  32. Hall RR et al. (1999) Neoadjuvant CMV chemotherapy for muscle invasive bladder cancer. Result of the International Trial. J Clin Oncol (in press)

    Google Scholar 

  33. Gospodarowicz M (1998) Locally advanced bladder cancer: radiation and chemotherapy. Eur Urol 33–27–31

    Article  PubMed  Google Scholar 

  34. Coppin CM, Gospodarowicz MK, James K et al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and radiation. J Clin Oncol 14:2901–2907

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. J. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pitié-Salpétrière Hospital SOMPS, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    David Khayat

  2. MD Anderson Cancer Center, Department of Breast Medical Oncology, University of Texas, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Gabriel N. Hortobagyi

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag France

About this chapter

Cite this chapter

Moore, M.J. (2000). Systemic Therapy of Bladder Cancer. In: Khayat, D., Hortobagyi, G.N. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 4. Springer, Paris. https://doi.org/10.1007/978-2-8178-0920-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0920-5_9

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-59692-6

  • Online ISBN: 978-2-8178-0920-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation